OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease

Bone Marrow Transplantation

Volumn 36, Issue 9, 2005, Pages 831-837

  Knop, S ^a   Hebart, H ^b   Gscheidle, H ^b   Holler, E ^c   Kolb, H J ^d   Niederwieser, D ^e   Einsele, H ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Graft versus host disease; Monoclonal antibody; OKT3; Stem cell transplantation

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; OKT 3; ORTHOCLONE; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; BRADYCARDIA; CANCER SURVIVAL; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LEUKEMIA REMISSION; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; RASH; RECIPIENT; RETROSPECTIVE STUDY; SALVAGE THERAPY; TACHYCARDIA; VOMITING; WHOLE BODY RADIATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MUROMONAB-CD3; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 27744586984     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705132     Document Type: Article

References (28)

1. McCaul KG, Nevill TJ, Barnett MJ et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit anti-thymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367-374.
2. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
3. Remberger M, Aschan J, Barkholt L et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001; 15: 147-153.
4. Ruutu T, Hermans J, van Biezen A et al. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 22: 614-615.
5. Herbelin C, Stephan JL, Donadieu J et al. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Bone Marrow Transplant 1994; 13: 563-569.
6. Tse JC, Moore TB. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Pharmacotherapy 1998; 18: 988-1000.
7. Przepiorka D, Phillips GL, Ratanatharathorn V et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92: 4066-4071.
8. Buysmann S, Bemelman FJ, Schellekens PT et al. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996; 87: 404-411.
9. Glucksberg H. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985; 313: 337-342.
10. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76: 1464-1472.
12. Goldstein G, Fuccello AJ, Norman DJ et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986; 42: 507-511.
13. Bach JF, Chatenoud L. Immunologic monitoring of Orthoclone OKT3-treated patients: The problem of antimonoclonal immune response. Transplant Proc 1987; 19 (Suppl. 1): 17-20.
14. Jeyarajah DR, Thistlethwaite Jr JR. General aspects of cytokine-release syndrome: Timing and incidence of symptoms. Transplant Proc 1993; 25 (Suppl. 1): 16-20.
15. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
16. Van Lint MT, Uderzo C, Locasciulli A et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
17. Racadot E, Milpied N, Bordigoni P et al. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: A multicentric pilot study including 15 patients. Bone Marrow Transplant 1995; 15: 669-677.
18. Deeg HJ, Loughran Jr TP, Storb R et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40: 162-166.
19. Gluckman E, Devergie A, Varin F et al. Treatment of steroid resistant severe acute graft-versus host disease with a monoclonal pan T OKT3 antibody. Exp Hematol 1984; 12 (Suppl. 15): 66-67.
20. Gratama JW, Jansen J, Lipovich RA et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effects on circulating T lymphocytes. Transplantation 1984; 38: 469-474.
21. Hebart H, Ehninger G, Schmidt H et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995; 15: 891-894.
22. Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 1989; 37: 871-899.
23. Conlon Jr J, Carmody M, Donohoe J et al. Cytomegalovirus infection as a complication of OKT3 therapy in kidney transplant recipients. Ir J Med Sci 1992; 161: 630-632.
24. Swinnen LJ. Transplantation-related lymphoproliferative disorder: A model for human immunodeficiency virus-related lymphomas. Semin Oncol 2000; 27: 402-408.
25. Carpenter PA, Appelbaum FR, Corey L et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712-2719.
26. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984-988.
27. Chatenoud L. Immunologic monitoring during OKT3 therapy. Clin Transplant 1993; 7: 422-430.
28. Waller EK, Langston AA, Lonial S et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation Biol. Blood Marrow Transplant 2003; 9: 460-471.